Daniel Aletaha

Professor of Rheumatology, Head of Rheumatology, Medical University Vienna, Austria;
Past-President of EULAR

[Daniel Aletaha @DanielAletaha]

Peter Mandl reframes the synovium as a “synovial interface” where biology, imaging & patient perception intersect. His new perspective challenges us to rethink how we assess inflammation beyond single measures and toward integrated monitoring: https://t.co/2oDH7xJc6i

[Daniel Aletaha @DanielAletaha]

Thirty years go by quickly. Building something that lasts does not. We recently celebrated 30 years of university rheumatology in Austria at the Josephinum in Vienna. From history to AI, imaging and patient partnership, one thing is clear: the discipline is not standing still!

[Daniel Aletaha @DanielAletaha]

International Women’s Day is a reminder that excellence in medicine depends on equality. In rheumatology, women lead research, shape clinical care, mentor the next generation and drive innovation. Our field is stronger because of it.
https://t.co/7sDKbNKTYf

[Daniel Aletaha @DanielAletaha]

Looking forward to a special conversation at the Day of MedUni Vienna (12 March 2026): Josef Smolen in the Alumni Club “Lebenswege”, reflecting on a career that helped shape modern rheumatology. Some careers define a field. This is one of them. Details:
https://t.co/dNJmm9y41I

[Daniel Aletaha @DanielAletaha]

I recently pitched our vision for a pan-EU clinical research ecosystem to boost Europe’s leadership in medical innovation, streamlined trials, stronger capacity, connected data, empowered patients. Watch here: https://t.co/wi77JJmV12

[Daniel Aletaha @DanielAletaha]

So many great impressions from the CCII fundraising dinner: I was thrilled to see researchers, clinicians & partners connect across disciplines and stakeholders. Collaborations like this drive better care for patients! Learn more: https://t.co/MxDo2H9mdJ

[Daniel Aletaha @DanielAletaha]

Today, on #MensHealthDay, let’s raise awareness of men-biased autoimmune diseases like axial spondylarthritis, and women-biased autoimmune diseases in men! https://t.co/U4bWBLoJFL

[Daniel Aletaha @DanielAletaha]

🔬Today is #WorldScienceDay, celebrating science as a force for peace, sustainability & inclusion.
Proud of how our work in rheumatology, autoimmunity & inflammation at @MedUni_Wien contributes to these goals.
🌍https://t.co/gJHvFZtuyA

[Daniel Aletaha @DanielAletaha]

🎉Warm congratulations to Prof. Josef S. Smolen, former Head of our Division, ranked #3 in Austria and Top 650 worldwide in the 2025 https://t.co/hJn1ektHLI Best Scientists list, a testament to his lasting impact and leadership in rheumatology.
🔗https://t.co/hGh64F1scB

[Daniel Aletaha @DanielAletaha]

🌍Calling all clinicians involved in Sjögren’s disease–related ILDcare!
Take part in our international survey on how ILD in SjD is detected, monitored & managed across regions.
🕒~10–15 min, your input matters!
👉https://t.co/SR1mu48Kgd

[Daniel Aletaha @DanielAletaha]

🌍 Today is #WorldPsoriasisDay, we stand with 125 million people worldwide living with psoriasis and psoriatic arthritis. It’s more than skin-deep: a systemic disease needing awareness, early screening & holistic care.
🔗https://t.co/tNuHFKon5K

[Daniel Aletaha @DanielAletaha]

Helga Lechner-Radner from our Division joined @ORF's Bewusst gesund to discuss “Leben mit Rheuma.”
She highlighted that rheumatic diseases go far beyond joint pain, early diagnosis and modern therapy can truly change lives:
🎥https://t.co/hjl0tsz6av

[Daniel Aletaha @DanielAletaha]

I recently shared my thoughts on Austria’s strong global role in rheumatology in my recent Schmerz Nachrichten interview, from @eular_org initiatives to digital innovation and equity in care. Grateful to all who make this collaboration possible. 🇦🇹
https://t.co/kYuOhTmzOx

[Daniel Aletaha @DanielAletaha]

📅Save the Date! The ÖGR Jahrestagung 2025 takes place 27–29 Nov, Tech Gate Vienna. Abstract deadline: 30 Sept. Join us to share research, connect, and explore innovations in rheumatology & rehabilitation.
👉Info: https://t.co/gn2aUorgHd

[Daniel Aletaha @DanielAletaha]

🤖✨Exciting news at @MedUni_Wien Rheumatology! We’ve welcomed ARTHUR, the ultrasound robot by @ROPCA3. ARTHUR reduces workload, standardizes imaging & enhances patient care, bringing AI & robotics into daily rheumatology practice.

[Daniel Aletaha @DanielAletaha]

At the Dresden Symposium on Autoantibodies 2025, Daniela Sieghart presented on biomarkers for RA treatment response, highlighting EU projects @SQUEEZE_project & AutoPiX. Our division drives precision medicine forward, tailoring care through innovative biomarkers.

[Daniel Aletaha @DanielAletaha]

New in Journal of Autoimmunity: our study on FAPI PET/CT in myositis-related ILD, led by Kastriot Kastrati & Peter Mandl. Findings show FAPI uptake predicts progression better than standard tools, promising step for personalized care. 📖 https://t.co/DLjnC7gjPY

[Daniel Aletaha @DanielAletaha]

📢 New from our Division of Rheumatology: Peter Mandl on the expanding role of ultrasound in rheumatology - beyond joints to glands, vessels, lungs & muscles. Real-time, radiation-free imaging for diagnosis & management. 🎥https://t.co/o1JqRGFk5v

[Daniel Aletaha @DanielAletaha]

Our study on how global recruitment patterns affect placebo response in RA trials has gained broad Austrian media coverage (@ORF, NÖN, SN & more). Great to see interest in how trial design impacts fair evaluation of new therapies! 🔗https://t.co/osMIqznJ85

[Daniel Aletaha @DanielAletaha]

Two new papers from our division show that recruiting RA & PsA trial patients in less affluent regions increase placebo rates - likely from limited treatment access. Trial design must adapt.
RA: https://t.co/jkrLRMeXdf
PsA: https://t.co/8SguP8Wr2x